Datopotamab deruxtecan: Regulatory decisions in US/Japan for HR+ and HER2 low or negative, 2/3L breast cancer (based on TROPION-Breast01 trial) in H2 FY2024 (Daiichi Sankyo) - Nov 7, 2024 - Q2 FY2024 Results
FDA approval • Japan approval • Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology
|